ReviewCurrent treatment options in neurology2016
Behçet's Disease and Nervous System Involvement.
Review in Current treatment options in neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 28 citations in OpenAlex.
- Neuro-behcet's syndrome: epidemiology, mechanisms, and emerging strategies in diagnosis and treatment.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Review
- Neurofilament Light Chain as a Potential Serum-Based Biomarker for Monitoring Disease Activity in Neuro-Behçet's Disease.Noro psikiyatri arsivi · 2026Article
- Neuro-Behçet's disease: an update of clinical diagnosis, biomarkers, and immunopathogenesis.Clinical and experimental immunology · 2025Review
- Diffusion Tensor Imaging in Parenchymal Neuro-Behçet's Disease.Noro psikiyatri arsivi · 2024Article
- Cerebrospinal fluid level of neurofilament light chain is associated with increased disease activity in neuro-Behçet's disease.Turkish journal of medical sciences · 2022Article
- Neuro-Behçet - Clinical and radiological findings in a Patient of Sub-saharan African origin.Radiology case reports · 2022Article
- Behçet's Disease in Children: Diagnostic and Management Challenges.Therapeutics and clinical risk management · 2020Review
- Treating the Different Phenotypes of Behçet's Syndrome.Frontiers in immunology · 2019Review
- Assessment of Cytokine Release against Oral Mucosal Cell Line Culture (TR146) Stimulated by Neutrophil Elastase Associated with Behcet's Disease.International journal of dentistry · 2019Article
- Wrist Drop as a Manifestation of Behçet's Disease.European journal of case reports in internal medicine · 2017Article
- Enhanced NLRP3 and DEFA1B Expression During the Active Stage of Parenchymal Neuro-Behçet's Disease.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementManagement of neuro-Behçet's disease can be divided into two stages: treatment of acute attacks and prevention of relapses. Treatment of acute attacks is accomplished by high-dose intravenous corticosteroids followed by maintenance treatment with oral steroids for 6-12 months depending on the type and severity of the neurological involvement. Relapses can be prevented by using immunosuppressants. Oral immunosuppressants such as azathioprine and mycophenolate are the most widely utilized agents for this purpose. Patients who are refractory or who cannot tolerate these medications can be managed by cyclophosphamide, interferon alpha, or anti-TNF-α monoclonal antibodies such as infliximab, etanercept, and adalimumab. Recent reports showed that newer agents such as tocilizumab, canakinumab, and anakinra, which exert their biological activity through IL-1 and IL-6 pathways, are also promising treatment alternatives for progressive or relapsing patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.